Amgen's Evolocumab slashes "bad" cholesterol by up to 66% in trial

Amgen's (AMGN) Evolocumab cut "bad" LDL cholesterol by 55-66% vs a placebo in three Phase III trials. The drug also didn't show any serious safety problems.

Amgen presented the data yesterday, fleshing out an earlier disclosure that the drug had achieved its main targets in five late-stage trials of 4,000 patients. Amgen is set to present data from the other two studies today.

Evolocumab is part of a new class of drugs called PCSK9 inhibitors, which block a protein that inhibits the ability of the liver to remove LDL from the blood.

Analysts have forecast that annual sales of each such drug could hit $3B or more. (PR)

From other sites
Comments (15)
  • TAS
    , contributor
    Comments (3996) | Send Message
    Wow. Another cholesterol reducing drug.


    How about finding a cure for the common cold?
    30 Mar 2014, 10:09 AM Reply Like
  • rrose39
    , contributor
    Comments (1078) | Send Message
    There's no cure for the common cold because that would require a 100+ valent vaccine, which would represent a tall challenge indeed to put together. Also, colds usually don't kill their victims. So there's not a lot of interest in devoting research efforts toward development of a vaccine.


    Heart attacks and strokes (both of which are thought to be associated with elevated cholesterol levels) are another matter altogether.
    30 Mar 2014, 10:32 PM Reply Like
  • Igraduatedcollegealready!
    , contributor
    Comments (265) | Send Message
    Colds don't kill! Cholesterol causes strokes and heart disease!
    30 Mar 2014, 11:10 AM Reply Like
  • tstreet
    , contributor
    Comments (1035) | Send Message
    Actually, the jury is at best out on whether or not cholesterol causes heart disease. They need another drug because the existing ones are selling so cheaply.
    30 Mar 2014, 12:01 PM Reply Like
  • TruffelPig
    , contributor
    Comments (4208) | Send Message
    Yes, the relationship between Cholesterol per se and clogged arteries is weak at best. Probably the anti inflammatory action of statins.
    30 Mar 2014, 01:33 PM Reply Like
  • mr clark
    , contributor
    Comments (727) | Send Message
    wow thats amazing, know what else does?


    eating vegetables
    30 Mar 2014, 11:53 AM Reply Like
  • hippie60
    , contributor
    Comment (1) | Send Message
    Sorry this targets Genetic high cholesterol no amount of veggies or exercise can help! If you do everything right and the other person eating everything wrong and your cholesterol is sky high as is everyone in your family. Do not judge what you don't consider!
    15 May 2014, 04:20 PM Reply Like
  • rambler1
    , contributor
    Comments (1054) | Send Message
    How much do people have to reduce cholesterol? I imagine the majority of the population has some degree of high cholesterol, but there are many generics out there that can easily drop figures by 20-40%, and are proven & safe. This will be a premium priced drug I imagine for the fringe. Otherwise it will be administered in very small dosages.
    30 Mar 2014, 12:06 PM Reply Like
  • D.Rapp
    , contributor
    Comments (180) | Send Message
    What idiotic comments (above) to what is clearly good news for shareholders and those with high cholesterol.
    30 Mar 2014, 12:50 PM Reply Like
  • tstreet
    , contributor
    Comments (1035) | Send Message
    Do some research and you may find that the comments are not so idiotic. Or refute the comments without engaging in personal attacks.
    30 Mar 2014, 04:37 PM Reply Like
  • anthonyk32792
    , contributor
    Comments (3) | Send Message
    Idiotic? The heavy cholesterol improvement margin justifies the heavy price tag for this drug, whereas the zero-cost substitution to that is simply eating better and exercising. And don't mix up the titles "shareholder" and "stakeholder" if you're going to baselessly call people idiotic for thinking more critically than you have.
    30 Mar 2014, 09:07 PM Reply Like
  • billy jones
    , contributor
    Comments (14) | Send Message
    This is a quite different drug than those previously made. It is a monoclonal antibody, biological agent, that has a completely different means of control. It may provide valuable for those for whom the current drugs have toxicities.
    30 Mar 2014, 09:12 PM Reply Like
  • rrose39
    , contributor
    Comments (1078) | Send Message
    Monoclonal antibody preparations are most often delivered by intravenous infusion, rather than the oral route typically associated with delivery of cholesterol-reducing drugs.


    IV infusion is not practical for routine home use.
    30 Mar 2014, 10:24 PM Reply Like
  • mitrado
    , contributor
    Comments (2033) | Send Message
    Is it me or Seeking Alpha is getting crowded by angry kindergarten kids who act like trolls, always quick to insult those who don't agree with their own opinions!?
    31 Mar 2014, 03:11 AM Reply Like
  • billy jones
    , contributor
    Comments (14) | Send Message
    Patients with an LDL cholesterol level of 75 mg per deciliter (1.9 mmol per liter) or higher were then randomly assigned in a 2:1 ratio to receive either evolocumab (420 mg) or placebo every 4 weeks. The primary end point was the percent change from baseline in LDL cholesterol, as measured by means of ultracentrifugation, at week 52.


    Every four weeks for an infusion is not that bad. Especially if they move to a self injectable format.
    1 Apr 2014, 03:05 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs